» Articles » PMID: 9671741

Biallelic Inactivation of HMLH1 by Epigenetic Gene Silencing, a Novel Mechanism Causing Human MSI Cancers

Overview
Specialty Science
Date 1998 Jul 22
PMID 9671741
Citations 199
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations of DNA mismatch repair genes, including the hMLH1 gene, have been linked to human colon and other cancers in which defective DNA repair is evidenced by the associated instability of DNA microsatellite sequences (MSI). Germ-line hMLH1 mutations are causally associated with inherited MSI colon cancer, and somatic mutations are causally associated with sporadic MSI colon cancer. Previously however, we demonstrated that in many sporadic MSI colon cancers hMLH1 and all other DNA mismatch repair genes are wild type. To investigate this class of tumors further, we examined a group of MSI cancer cell lines, most of which were documented as established from antecedent MSI-positive malignant tumors. In five of six such cases we found that hMLH1 protein was absent, even though hMLH1-coding sequences were wild type. In each such case, absence of hMLH1 protein was associated with the methylation of the hMLH1 gene promoter. Furthermore, in each case, treatment with the demethylating agent 5-azacytidine induced expression of the absent hMLH1 protein. Moreover, in single cell clones, hMLH1 expression could be turned on, off, and on again by 5-azacytidine exposure, washout, and reexposure. This epigenetic inactivation of hMLH1 additionally accounted for the silencing of both maternal and paternal tumor hMLH1 alleles, both of which could be reactivated by 5-azacytidine. In summary, substantial numbers of human MSI cancers appear to arise by hMLH1 silencing via an epigenetic mechanism that can inactivate both of the hMLH1 alleles. Promoter methylation is intimately associated with this epigenetic silencing mechanism.

Citing Articles

Genomic instability as a driver and suppressor of anti-tumor immunity.

Requesens M, Foijer F, Nijman H, de Bruyn M Front Immunol. 2024; 15:1462496.

PMID: 39544936 PMC: 11562473. DOI: 10.3389/fimmu.2024.1462496.


Recapitulating the adenoma-carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids.

Mizutani T, Boretto M, Lim S, Drost J, Gonzalez D, Oka R Nat Cancer. 2024; 5(12):1852-1867.

PMID: 39487295 PMC: 11663794. DOI: 10.1038/s43018-024-00841-x.


Unique miRNA Expression Profile in MSI- and EMAST-Unstable Sporadic Colon Cancer.

Marinovic S, Derfi K, Skrtic A, Poljak M, Kapitanovic S Genes (Basel). 2024; 15(8).

PMID: 39202367 PMC: 11353743. DOI: 10.3390/genes15081007.


Treatment of Microsatellite-Unstable Rectal Cancer in Sporadic and Hereditary Settings.

Anderson C, Liska D Clin Colon Rectal Surg. 2024; 37(4):233-238.

PMID: 38882941 PMC: 11178385. DOI: 10.1055/s-0043-1770717.


Evaluating the utility of promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).

Nakasone E, Zemla T, Yu M, Lin S, Ou F, Carter K Epigenetics. 2024; 19(1):2349980.

PMID: 38716804 PMC: 11085945. DOI: 10.1080/15592294.2024.2349980.


References
1.
WILLSON J, Bittner G, Oberley T, Meisner L, Weese J . Cell culture of human colon adenomas and carcinomas. Cancer Res. 1987; 47(10):2704-13. View

2.
Herman J, Umar A, Polyak K, Graff J, Ahuja N, Issa J . Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998; 95(12):6870-5. PMC: 22665. DOI: 10.1073/pnas.95.12.6870. View

3.
Parsons R, Li G, Longley M, Fang W, Papadopoulos N, Jen J . Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 1993; 75(6):1227-36. DOI: 10.1016/0092-8674(93)90331-j. View

4.
Bhattacharyya N, Skandalis A, Ganesh A, Groden J, Meuth M . Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci U S A. 1994; 91(14):6319-23. PMC: 44193. DOI: 10.1073/pnas.91.14.6319. View

5.
Koi M, Umar A, Chauhan D, Cherian S, Carethers J, Kunkel T . Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994; 54(16):4308-12. View